BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15470338)

  • 1. Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass.
    Pretorius M; McFarlane JA; Vaughan DE; Brown NJ; Murphey LJ
    Clin Pharmacol Ther; 2004 Oct; 76(4):379-87. PubMed ID: 15470338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass.
    Pretorius M; Murphey LJ; McFarlane JA; Vaughan DE; Brown NJ
    Circulation; 2003 Dec; 108(25):3079-83. PubMed ID: 14656921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine-related hypotension after cardiopulmonary bypass.
    Pretorius M; Scholl FG; McFarlane JA; Murphey LJ; Brown NJ
    Clin Pharmacol Ther; 2005 Nov; 78(5):477-85. PubMed ID: 16321614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of ACE inhibition on myocardial damage, the Kallikrein-Kinin system and hemostasis during cardiopulmonary bypass surgery.
    Walter T; Helber U; Bail D; Heller W; Hoffmeister HM
    Thorac Cardiovasc Surg; 2002 Jun; 50(3):150-4. PubMed ID: 12077687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic vasopressin in patients receiving the angiotensin-converting enzyme inhibitor ramipril undergoing coronary artery bypass graft surgery.
    Hasija S; Makhija N; Choudhury M; Hote M; Chauhan S; Kiran U
    J Cardiothorac Vasc Anesth; 2010 Apr; 24(2):230-8. PubMed ID: 19875309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibition improves venous endothelial dysfunction in chronic smokers.
    Chalon S; Moreno H; Hoffman BB; Blaschke TF
    Clin Pharmacol Ther; 1999 Mar; 65(3):295-303. PubMed ID: 10096262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure.
    Cruden NL; Tse GH; Fox KA; Ludlam CA; Megson I; Newby DE
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):772-7. PubMed ID: 15681300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers: smoking, thrombin, and vascular responses in vivo.
    Lang NN; Gudmundsdóttir IJ; Boon NA; Ludlam CA; Fox KA; Newby DE
    J Am Coll Cardiol; 2008 Jul; 52(1):33-9. PubMed ID: 18582632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin.
    Brown NJ; Ryder D; Gainer JV; Morrow JD; Nadeau J
    J Pharmacol Exp Ther; 1996 Nov; 279(2):703-12. PubMed ID: 8930174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
    Walter T; Szabo S; Kazmaier S; Suselbeck T; Borggrefe M; Hoffmeister HM
    Thorac Cardiovasc Surg; 2009 Sep; 57(6):368-71. PubMed ID: 19707983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative angiotensin-converting enzyme inhibitors protect myocardium from ischemia during coronary artery bypass graft surgery.
    Benedetto U; Melina G; Capuano F; Comito C; Bianchini R; Simon C; Refice S; Angeloni E; Sinatra R
    J Cardiovasc Med (Hagerstown); 2008 Nov; 9(11):1098-103. PubMed ID: 18852580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative Angiotensin-converting enzyme inhibitors and acute kidney injury after coronary artery bypass grafting.
    Benedetto U; Sciarretta S; Roscitano A; Fiorani B; Refice S; Angeloni E; Sinatra R
    Ann Thorac Surg; 2008 Oct; 86(4):1160-5. PubMed ID: 18805152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin.
    Nagai N; Oike Y; Izumi-Nagai K; Koto T; Satofuka S; Shinoda H; Noda K; Ozawa Y; Inoue M; Tsubota K; Ishida S
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):2321-6. PubMed ID: 17460297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinin-related effects of angiotensin-converting enzyme inhibition.
    Bönner G
    Clin Physiol Biochem; 1990; 8 Suppl 1():6-15. PubMed ID: 2257722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of angiotensin converting enzyme insertion/deletion polymorphism on long-term total graft occlusion after coronary artery bypass surgery.
    Dayi SU; Tartan Z; Terzi S; Kasikcioglu H; Uyarel H; Orhan G; Alper AT; Ciloglu F; Cam N
    Heart Surg Forum; 2005; 8(5):E373-7. PubMed ID: 16146835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin.
    Murphey LJ; Gainer JV; Vaughan DE; Brown NJ
    Circulation; 2000 Aug; 102(8):829-32. PubMed ID: 10952948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term angiotensin-converting enzyme inhibitor treatment attenuates adrenergic responsiveness without altering hemodynamic control in patients undergoing cardiac surgery.
    Licker M; Neidhart P; Lustenberger S; Valloton MB; Kalonji T; Fathi M; Morel DR
    Anesthesiology; 1996 Apr; 84(4):789-800. PubMed ID: 8638832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
    Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
    J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.